

Title (en)

USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION

Title (de)

VERWENDUNG VON LCK SH2 SPEZIFISCHEN VERBINDUNGEN ZUR BEHANDLUNG VON AUTOIMMUNKRANKHEITEN UND ALLOPLASTISCHEN ABSTOPREAKTIONEN

Title (fr)

UTILISATION DE COMPOSES SPECIFIQUES COMPORTANT LCK SH2 POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET DU REJET D'ALLOGREFFES

Publication

EP 0809490 A4 19991020 (EN)

Application

EP 96905494 A 19960209

Priority

- US 9601964 W 19960209
- US 38638195 A 19950210
- US 40022095 A 19950307
- US 49735795 A 19950630

Abstract (en)

[origin: WO9624343A1] Invented is a method of treating autoimmune diseases in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain, and, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such lck SH2 domain.

IPC 1-7

A61K 31/00

IPC 8 full level

A61K 31/12 (2006.01); **C07D 207/50** (2006.01); **A61K 31/165** (2006.01); **A61K 31/166** (2006.01); **A61K 31/195** (2006.01); **A61K 31/40** (2006.01); **A61K 31/435** (2006.01); **A61K 31/437** (2006.01); **A61K 31/50** (2006.01); **A61K 38/45** (2006.01); **A61K 45/00** (2006.01); **A61P 29/00** (2006.01); **A61P 37/00** (2006.01); **A61P 43/00** (2006.01); **C07D 495/14** (2006.01); **C07D 495/22** (2006.01); **C12P 21/00** (2006.01); **G01N 33/15** (2006.01); **G01N 33/53** (2006.01); **G01N 33/543** (2006.01); **C12R 1/19** (2006.01)

CPC (source: EP KR)

A61K 31/00 (2013.01 - KR); **A61K 31/12** (2013.01 - EP); **A61K 31/166** (2013.01 - EP); **A61K 31/195** (2013.01 - EP); **A61K 31/40** (2013.01 - EP); **A61K 31/437** (2013.01 - EP); **A61K 31/50** (2013.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

Citation (search report)

- [X] WO 9407913 A1 19940414 - WARNER LAMBERT CO [US]
- [PX] WO 9525118 A2 19950921 - TRUSTEES OF TUFTS UNIVERSITY [US]
- [PX] US 5710129 A 19980120 - LYNCH BERKLEY A [US], et al
- See also references of WO 9624343A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9624343 A1 19960815; AU 4923796 A 19960827; BR 9607614 A 19980609; CA 2212645 A1 19960815; EP 0809490 A1 19971203; EP 0809490 A4 19991020; EP 0811159 A1 19971210; FI 973259 A0 19970807; FI 973259 A 19971008; HU P9802078 A2 19981228; HU P9802078 A3 19990428; JP H10513474 A 19981222; JP H10513564 A 19981222; KR 19980702115 A 19980715; NO 973659 D0 19970808; NO 973659 L 19971008

DOCDB simple family (application)

US 9601964 W 19960209; AU 4923796 A 19960209; BR 9607614 A 19960209; CA 2212645 A 19960209; EP 96905494 A 19960209; EP 96906615 A 19960212; FI 973259 A 19970807; HU P9802078 A 19960209; JP 52448696 A 19960209; JP 52449396 A 19960212; KR 19970705510 A 19970809; NO 973659 A 19970808